Literature DB >> 19735757

Analysis of biomarkers after intramuscular injection of Vaxfectin-formulated hCMV gB plasmid DNA.

Adrián Vilalta1, Mark Shlapobersky, Qun Wei, Rodrick Planchon, Alain Rolland, Sean Sullivan.   

Abstract

Cationic lipids have been used as delivery systems to enhance the performance of vaccines and immunotherapeutics. However, little is known about the effect of administration of cationic lipid-formulated vaccines on gene expression. This study used DNA microarrays (39,000 transcripts) to characterize early changes in gene expression patterns in mouse muscle 1 and 2 days after intramuscular (i.m.) injection of a hCMV gB plasmid DNA (pDNA) vaccine formulated with the cationic lipid system Vaxfectin; gene expression profiles were compared to those obtained after i.m. injection of pDNA in PBS. Analysis of the DNA microarray data indicated that approximately 1% of the represented transcripts were modulated at least 2-fold compared to the PBS samples at both time points. Functional analysis of the modulated genes revealed that transcripts involved in antigen processing and presentation, apoptosis and the Toll-like receptor pathway were significantly enriched. In addition, confirmation of local and systemic modulation of subsets of biomarkers was achieved using Real-Time PCR and Cytometric Bead Assays. Time course and magnitude of cellular infiltration (F4/80+ and CD11b+ cells) to the injection site was changed in response to formulation of hCMVgB pDNA with Vaxfectin. Since the expression level of the pDNA-encoded transgene in the muscle was not affected by formulation Vaxfectin mechanism of action is expected to rely primarily on modulation of immune pathways and not on an increase in transfection of the antigen-encoding pDNA. Taken together, these data help explain the Vaxfectin-dependent robust enhancement of immune responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19735757     DOI: 10.1016/j.vaccine.2009.08.075

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.

Authors:  Jukka Hartikka; Vesselina Bozoukova; Jane Morrow; Denis Rusalov; Mark Shlapobersky; Qun Wei; Sou Boutsaboualoy; Ming Ye; Mary K Wloch; John Doukas; Sean Sullivan; Alain Rolland; Larry R Smith
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

Review 2.  Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases.

Authors:  Thomas Grunwald; Sebastian Ulbert
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30

Review 3.  Non-viral COVID-19 vaccine delivery systems.

Authors:  Kyung Soo Park; Xiaoqi Sun; Marisa E Aikins; James J Moon
Journal:  Adv Drug Deliv Rev       Date:  2020-12-17       Impact factor: 17.873

4.  Effective usage of cationic derivatives of polyprenols as carriers of DNA vaccines against influenza virus.

Authors:  Anna Stachyra; Monika Rak; Patrycja Redkiewicz; Zbigniew Madeja; Katarzyna Gawarecka; Tadeusz Chojnacki; Ewa Świeżewska; Marek Masnyk; Marek Chmielewski; Agnieszka Sirko; Anna Góra-Sochacka
Journal:  Virol J       Date:  2017-09-02       Impact factor: 4.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.